Published originally by Logos Technologies prior to Instem ownership, included here for information purposes

Logos Technologies Signs Deal With Second Singaporean Site For ALPHADAS® eSource And Pro-Active EDC

8th August 2011

It is announced today that a second site in Singapore has entered into an agreement with Logos Technologies for its market leading, early phase, e-source data capture system and site automation software suite, ALPHADAS which gives clinical research sites unsurpassed tools to accelerate and streamline their clinical trial operations and service.

Mark Cusack, VP of Business Development at Logos Technologies said, “We are delighted to welcome this new site to our growing list of clients and look forward to working in collaboration with them to provide their Sponsors with faster, cleaner and more accurate data”. He continues, “We are very excited to be working with this site in Singapore as it forms a key part of our ongoing business plan and expansion into Asia.”

ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials which has achieved great success. It is a market proven solution that offers a depth of functionality other systems cannot provide. In addition, through its modular and flexible structure ALPHADAS can be tailored to fit a client’s individual needs. It is a system that 'fits all', it can be installed progressively in modules, meeting both a clients’ immediate requirements but also their longer term goals, it is a solution that can be used by all companies, big and small. The dedicated team behind ALPHADAS are Experts in Early Phase EDC and provide an unrivalled level of service, experience and expertise to its clients. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it the ‘System of Choice’ for early phase EDC.

Press Contact:

Instem
Angela King
angela.king@instem.com